GO:0032959 inositol trisphosphate biosynthetic process: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032959 (inositol trisphosphate biosynthetic process) describes the chemical reactions and pathways that produce inositol trisphosphate (IP3), a key second messenger.
• IP3 is generated mainly by phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2).
• IP3 triggers calcium release from the endoplasmic reticulum by binding to IP3 receptors (ITPRs), regulating diverse cellular processes.
• Dysregulation of IP3 biosynthesis and signaling is linked to cancer, cardiac disease, and neurological disorders.
• Key genes include PLC family members (e.g., PLCB1, PLCG1), ITPR1-3, and kinases such as IPMK and ITPKA/ITPKB.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of IP3 pathway genes in disease and physiology.
Description
Inositol trisphosphate (IP3) is a soluble second messenger that controls calcium release from intracellular stores and influences many cellular functions, including secretion, contraction, fertilization, and gene expression. The biosynthetic process that produces IP3 is annotated as GO:0032959 (inositol trisphosphate biosynthetic process), a biological process term that captures the enzymatic steps leading to IP3 formation. Understanding this process is essential because IP3 levels and dynamics are tightly regulated and their perturbation underlies multiple human diseases.
inositol trisphosphate biosynthetic process At A Glance
| GO ID | GO:0032959 |
|---|---|
| GO term | inositol trisphosphate biosynthetic process |
| Ontology | biological_process |
| Synonym | IP3 biosynthesis; inositol trisphosphate synthesis; myo-inositol trisphosphate biosynthetic process |
| Major function | Production of inositol trisphosphate (IP3), a calcium-mobilizing second messenger |
| Key enzymes | Phospholipase C (PLC) family, inositol polyphosphate multikinase (IPMK), ITPKA/ITPKB |
| Key receptors | IP3 receptors (ITPR1, ITPR2, ITPR3) |
| Pathway context | Phosphoinositide signaling; calcium signaling |
| Disease relevance | Cancer, cardiac hypertrophy, neurodegeneration |
What Is GO:0032959?
GO:0032959 (inositol trisphosphate biosynthetic process) is defined as the chemical reactions and pathways resulting in the formation of inositol trisphosphate, a cyclohexanehexol with three phosphate groups. This process primarily involves the phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce IP3 and diacylglycerol, as well as additional phosphorylation steps that generate IP3 isomers.
Why Is inositol trisphosphate biosynthetic process Important in Cell Biology?
The inositol trisphosphate biosynthetic process is central to calcium signaling, which regulates virtually every aspect of cell physiology. Because IP3 production is the rate-limiting step for IP3 receptor-mediated calcium release, its dysregulation contributes to diseases ranging from cancer to heart failure and neurological disorders. Researchers studying this process can identify therapeutic targets and biomarkers by manipulating the genes involved in IP3 biosynthesis.
• Controls intracellular calcium release, affecting secretion, contraction, and fertilization.
• Regulates cell growth, proliferation, and apoptosis, with implications for cancer.
• Modulates cardiac contractility and hypertrophy; IP3 receptors are implicated in heart disease.
• Influences neuronal signaling and astrocytic calcium waves, relevant to neurodegeneration.
• Provides targets for drug discovery in cardiovascular and neurological disorders.
• Enables mechanistic studies using CRISPR to dissect gene function in IP3 biosynthesis.
• Links phosphoinositide metabolism to metabolic diseases such as hepatic lipid homeostasis.
• IP3-binding proteins beyond canonical receptors expand signaling complexity.
What Happens During inositol trisphosphate biosynthetic process?
Substrate availability and PIP2 hydrolysis
In simple terms: The process starts when a lipid called PIP2 is cut into two pieces, one of which is IP3.
The primary route for IP3 biosynthesis is the phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol. PLC enzymes are activated by diverse upstream signals, including G protein-coupled receptors and receptor tyrosine kinases, making IP3 production a tightly regulated event.
Alternative phosphorylation pathways
In simple terms: IP3 can also be made by adding phosphate groups to other inositol lipids or soluble inositol phosphates.
In addition to PLC-mediated hydrolysis, IP3 isomers can be generated through phosphorylation of inositol polyphosphates by kinases such as inositol polyphosphate multikinase (IPMK) and ITPKA/ITPKB. These alternative routes contribute to the cellular pool of IP3 and its isomers, which may have distinct signaling roles.
Calcium release and signal propagation
In simple terms: Once IP3 is made, it binds to receptors on calcium stores and releases calcium into the cell.
Newly synthesized IP3 diffuses to the endoplasmic reticulum, where it binds IP3 receptors (ITPR1, ITPR2, ITPR3), triggering calcium release into the cytoplasm. This calcium signal is then decoded by downstream effectors to control processes such as secretion, contraction, and gene expression.
Termination and recycling
In simple terms: The signal is turned off when IP3 is modified or broken down.
IP3 signaling is terminated by dephosphorylation via inositol polyphosphate 5-phosphatases and by phosphorylation to inositol tetrakisphosphate, allowing the system to reset. Proper termination is essential to prevent sustained calcium elevation, which can be toxic.
Key Genes Involved in GO:0032959 inositol trisphosphate biosynthetic process
The following genes encode enzymes and receptors that directly participate in or regulate the inositol trisphosphate biosynthetic process and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLCB1 | Phospholipase C beta 1; hydrolyzes PIP2 to IP3 | G protein-coupled receptor signaling; neuronal function |
| PLCG1 | Phospholipase C gamma 1; hydrolyzes PIP2 to IP3 | Receptor tyrosine kinase signaling; cancer |
| PLCD1 | Phospholipase C delta 1; produces IP3 | Calcium signaling; differentiation |
| IPMK | Inositol polyphosphate multikinase; generates IP3 isomers | Nuclear signaling; metabolism |
| ITPKA | Inositol-trisphosphate 3-kinase A; phosphorylates IP3 | Neuronal calcium signaling |
| ITPKB | Inositol-trisphosphate 3-kinase B; phosphorylates IP3 | Immune cell function; calcium homeostasis |
| ITPR1 | IP3 receptor type 1; mediates calcium release | Neurodegeneration; ataxia |
| ITPR2 | IP3 receptor type 2; mediates calcium release | Exocrine secretion; cardiac function |
| ITPR3 | IP3 receptor type 3; mediates calcium release | Immune function; cancer |
| ORMDL2 | Regulates sphingolipid metabolism; affects IP3 signaling | Hepatic lipid homeostasis |
| CALM1 | Calmodulin; modulates IP3 receptors | Calcium feedback regulation |
| ATP2A2 | SERCA pump; refills calcium stores | Cardiac function; calcium cycling |
| RYR2 | Ryanodine receptor; calcium-induced calcium release | Cardiac excitation-contraction coupling |
| PRKCA | Protein kinase C; activated by DAG co-product | Downstream signaling |
| TRPC3 | Store-operated calcium channel; modulated by IP3 | Calcium influx; neuronal function |
| GRM1 | Metabotropic glutamate receptor; activates PLC | Neuronal IP3 production |
| AGTR1 | Angiotensin II receptor; activates PLC | Cardiac hypertrophy; IP3 signaling |
How Is inositol trisphosphate biosynthetic process Regulated?
The inositol trisphosphate biosynthetic process is regulated at multiple levels. Upstream, G protein-coupled receptors and receptor tyrosine kinases activate phospholipase C enzymes, which hydrolyze PIP2 to produce IP3. Calcium itself feeds back to modulate PLC activity and IP3 receptor sensitivity. Kinases such as ITPKA and ITPKB phosphorylate IP3, reducing its availability and terminating signaling. Additionally, IP3 receptor activity is regulated by phosphorylation, ATP, and calcium, shaping the spatial and temporal patterns of calcium release.
inositol trisphosphate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITPR1 | Spinocerebellar ataxia; neurodegeneration | Knockout mouse; patient iPSC-derived neurons |
| PLCG1 | Cancer; tumor growth | Knockout cancer cell lines; xenograft models |
| ITPR2 | Cardiac hypertrophy; arrhythmia | Cardiomyocyte-specific knockout; overexpression |
| ITPKB | Immune disorders; calcium dysregulation | Knockout mice; T cell models |
| ORMDL2 | Hepatic lipid homeostasis | Liver-specific knockout; overexpression |
Cancer
Altered IP3 biosynthesis and IP3 receptor function contribute to cancer cell proliferation, survival, and migration. For example, PLCG1 mutations and overexpression are observed in various tumors, and IP3 receptor subtypes can promote or suppress tumorigenesis depending on context.
Cardiac disease
IP3 receptors in cardiomyocytes regulate calcium handling and are implicated in cardiac hypertrophy and arrhythmias. Dysregulated IP3 production can exacerbate pathological remodeling, making pathway components potential therapeutic targets.
Neurological disorders
IP3-mediated calcium signaling is critical for neuronal plasticity and astrocytic function. Mutations in ITPR1 cause spinocerebellar ataxia, and altered IP3 signaling is linked to neurodegeneration.
Metabolic disease
IP3 signaling intersects with lipid metabolism; ORMDL2, a regulator of sphingolipid synthesis, affects hepatic lipid homeostasis and may influence IP3 pathways.
From inositol trisphosphate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLCB1 affect IP3 production and calcium signaling? | CRISPR knockout in neuronal cell lines |
| How do point mutations in ITPR1 alter calcium release? | CRISPR point mutation knock-in in iPSCs |
| Can tagging ITPR1 with a fluorescent protein reveal real-time IP3 dynamics? | CRISPR knock-in of GFP tag |
| Does overexpression of PLCG1 drive cancer cell proliferation? | CRISPR overexpression in cancer cell lines |
| What is the role of ITPKB in immune cell calcium homeostasis? | Knockout mouse models |
| How does ORMDL2 regulate IP3-linked lipid metabolism? | Liver-specific knockout and overexpression |
How to Study the inositol trisphosphate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium dynamics | Live-cell signaling studies |
| IP3 ELISA | IP3 concentration | Quantifying IP3 production |
| CRISPR knockout | Gene function loss | Causal gene analysis |
| CRISPR knock-in | Tagged or mutant protein expression | Real-time imaging; disease modeling |
| RNA-seq | Transcriptional changes | Pathway profiling after perturbation |
| Proteomics | Protein interactions and abundance | Mapping IP3 receptor complexes |
| CRISPR library screen | Phenotypic selection | Discovery of novel regulators |
Calcium imaging
Fluorescent calcium indicators (e.g., GCaMP) allow real-time visualization of IP3-induced calcium release in live cells. This method is widely used to assess the functional consequences of manipulating IP3 biosynthesis genes.
IP3 measurement
IP3 levels can be quantified using radioreceptor assays, ELISA, or mass spectrometry, providing direct readouts of biosynthetic activity. These methods are essential for validating CRISPR perturbations.
Genetic screens
CRISPR library screening can identify genes that regulate IP3 production and calcium signaling, uncovering novel pathway components. Such screens are powerful for unbiased discovery.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can map IP3 receptor interactomes and identify IP3-binding proteins beyond canonical receptors. This helps define the broader signaling network.
How CRISPR Can Be Used to Study GO:0032959 inositol trisphosphate biosynthetic process
Knockout
CRISPR knockout of genes such as PLCB1, PLCG1, or ITPR1 enables loss-of-function studies to determine their necessity for IP3 biosynthesis and calcium signaling. Knockout cell lines and animal models are widely used to dissect pathway contributions to disease.
Point Mutation
Introducing disease-associated point mutations (e.g., in ITPR1) via CRISPR base editing or homology-directed repair allows precise modeling of altered IP3 receptor function and calcium handling. Such models are valuable for testing targeted therapies.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous IP3 receptor loci permits real-time visualization of protein localization and dynamics without overexpression artifacts. This approach is ideal for studying IP3 signaling in native contexts.
Overexpression
CRISPR-mediated overexpression of PLC enzymes or IP3 receptors can amplify IP3 production and calcium signals, helping to identify gain-of-function phenotypes in cancer and cardiac disease. Overexpression models complement knockout studies.
How EDITGENE Supports inositol trisphosphate biosynthetic process Research
Researchers studying inositol trisphosphate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in IP3 production, calcium signaling, or disease phenotypes. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for inositol trisphosphate biosynthetic process research.
Frequently Asked Questions About inositol trisphosphate biosynthetic process
What is inositol trisphosphate biosynthetic process?
It is the biological process (GO:0032959) that produces inositol trisphosphate (IP3), a calcium-mobilizing second messenger, primarily through phospholipase C-mediated hydrolysis of PIP2.
What genes are involved in inositol trisphosphate biosynthetic process?
Key genes include PLCB1, PLCG1, PLCG2, IPMK, ITPKA, ITPKB, and IP3 receptors ITPR1, ITPR2, ITPR3.
How is IP3 produced in cells?
IP3 is mainly produced when phospholipase C enzymes hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and diacylglycerol.
What is the role of IP3 in calcium signaling?
IP3 binds to IP3 receptors on the endoplasmic reticulum, triggering calcium release into the cytoplasm and activating downstream signaling.
Which diseases are linked to IP3 biosynthesis?
Dysregulated IP3 signaling is implicated in cancer, cardiac hypertrophy, spinocerebellar ataxia, and neurodegenerative disorders.
How can CRISPR be used to study IP3 biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of IP3 pathway genes to study their function and disease relevance.
What are the main enzymes in IP3 biosynthesis?
Phospholipase C (PLC) family enzymes are the primary producers of IP3; kinases such as IPMK and ITPKA/ITPKB also generate IP3 isomers.
What is the difference between IP3 and PIP2?
PIP2 is a membrane phospholipid that is cleaved by PLC to produce IP3 and diacylglycerol; IP3 is the soluble second messenger.
How is IP3 signaling terminated?
IP3 is dephosphorylated by 5-phosphatases or phosphorylated by 3-kinases, terminating calcium release.
What model systems are used to study IP3 biosynthesis?
Common models include CRISPR-engineered cell lines, knockout mice, and patient-derived iPSCs, combined with calcium imaging and IP3 quantification.
Conclusion
The inositol trisphosphate biosynthetic process (GO:0032959) is a fundamental signaling pathway that controls calcium release and influences diverse physiological and pathological processes. Advances in CRISPR gene editing now allow precise dissection of the genes involved, from PLC enzymes to IP3 receptors, in relevant disease models. Targeting this pathway holds promise for therapeutic development in cancer, cardiac disease, and neurodegeneration.
References
- 1. Berridge MJ. 2016. The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease.. Physiol Rev 96(4):1261-96 PMID: 27512009
- 2. Zhou B et al.. 2022. Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis.. Nat Metab 4(9):1185-1201 PMID: 36050503
- 3. Mackrill JJ. 2023. Non-inositol 1,4,5-trisphosphate (IP(3)) receptor IP(3)-binding proteins.. Biochim Biophys Acta Mol Cell Res 1870(5):119470 PMID: 37011730
- 4. Parys JB et al.. 2012. Inositol 1,4,5-trisphosphate and its receptors.. Adv Exp Med Biol 740:255-79 PMID: 22453946
- 5. Demydenko K et al.. 2022. Inositol 1,4,5-trisphosphate receptors in cardiomyocyte physiology and disease.. Philos Trans R Soc Lond B Biol Sci 377(1864):20210319 PMID: 36189803
- 6. Berridge MJ. 2009. Inositol trisphosphate and calcium signalling mechanisms.. Biochim Biophys Acta 1793(6):933-40 PMID: 19010359
- 7. Hamada K et al.. 2020. IP(3) Receptor Plasticity Underlying Diverse Functions.. Annu Rev Physiol 82:151-176 PMID: 31730387
- 8. Okubo Y et al.. 2020. Visualization of astrocytic intracellular Ca(2+) mobilization.. J Physiol 598(9):1671-1681 PMID: 30825213
